No abstract available
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Benzamides
-
Drug Administration Schedule
-
Female
-
Fusion Proteins, bcr-abl / antagonists & inhibitors
-
Fusion Proteins, bcr-abl / genetics
-
Gene Expression Regulation, Leukemic / drug effects
-
Humans
-
Imatinib Mesylate
-
Kaplan-Meier Estimate
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
-
Male
-
Middle Aged
-
Piperazines / administration & dosage
-
Piperazines / therapeutic use*
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / therapeutic use
-
Pyrimidines / administration & dosage
-
Pyrimidines / therapeutic use*
-
Recurrence
-
Remission Induction
-
Time Factors
-
Treatment Outcome
Substances
-
Benzamides
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Imatinib Mesylate
-
Fusion Proteins, bcr-abl